L-DOPA (L-3,4-dihydroxyphenylalanine) remains the most effective drug for the treatment of Parkinson's disease. However, chronic use causes dyskinesia, a complex motor phenomenon that consists of ...
Previous studies in a rat model of Parkinson disease (PD) have shown that dyskinesia induced by L-DOPA—a treatment-limiting adverse effect of long-term administration—is caused by the release ...
The odds ratio for exposure to L-dopa in the IPD patients with PN was 12.4 (95% confidence interval, 1.4–109.1). There were no differences between the groups in the use of other PD drugs ...
L-dopa remains the most powerful antiparkinsonian agent, but a minority of treated patients develop disabling motor response complications. Alternatives to L-dopa for initial treatment of ...
Valentino Stella served as a consultant in developing Vyalev, which is delivered subcutaneously to Parkinson’s patients through a wearable pump that’s smaller, more comfortable and effective at ...
In a public advisory, Health Canada says various ingredients were found in the unauthorized health products, including acetaminophen, DHEA (dehydroepiandrosterone), levodopa (aka L-dopa ...